Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results

被引：1

作者：

Sitbon, Olivier ^{[1
]}

Channick, Richard ^{[2
]}

Chin, Kelly ^{[3
]}

Frey, Aline ^{[4
]}

Galie, Nazzareno ^{[5
]}

Ghofrani, Hossein-Ardeschir ^{[6
]}

Hoeper, Marius M. ^{[7
,8
]}

Lang, Irene ^{[9
]}

Le Brun, Franck-Olivier ^{[4
]}

McLaughlin, Vallerie ^{[10
]}

Preiss, Ralph ^{[4
]}

Rubin, Lewis J. ^{[11
]}

Simonneau, Gerald ^{[1
]}

Tapson, Victor ^{[12
]}

Gaine, Sean ^{[13
]}

机构：

[1] Univ Paris Sud, Hop Univ Bicetre, Le Kremlin Bicetre, France

[2] Massachusetts Gen Hosp, Pulm & Crit Care, Boston, MA 02114 USA

[3] Univ Texas Southwestern Med Ctr Dallas, Pulm Hypertens Program, Dallas, TX 75390 USA

[4] Actel Pharmaceut Ltd, Clin Res, Allschwil, Switzerland

[5] Univ Bologna, Ist Malattie Apparato Cardiovasc, Bologna, Italy

[6] UGMLC, Giessen, Germany

[7] Hannover Med Sch, Dept Resp Med, Hannover, Germany

[8] German Ctr Lung Res, Hannover, Germany

[9] Med Univ Vienna, AKH, Dept Internal Med 2, Div Cardiol, Vienna, Austria

[10] Univ Michigan Hlth Syst, Div Cardiovasc Med, Ann Arbor, MI USA

[11] Univ Calif San Diego, Div Pulm & Crit Care Med, San Diego, CA 92103 USA

[12] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA

[13] Mater Misericordiae Univ Hosp, Natl Pulm Hypertens Unit, Dublin, Ireland

来源：

EUROPEAN RESPIRATORY JOURNAL | 2015年 / 46卷

关键词：

Pulmonary hypertension;

D O I：

10.1183/13993003.congress-2015.OA4995

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

OA4995

引用

页数：3

共 50 条

[1] Effect of selexipag on long-term outcomes in patients with pulmonary arterial hypertension (PAH) receiving one, two or no PAH therapies at baseline: results from the GRIPHON study
Lang, I.
Gaine, S.
Galie, N.
Ghofrani, H. A.
Le Brun, F. O.
McLaughlin, V.
Rubin, L. J.
Simonneau, G.
Sitbon, O.
Hoeper, M.
EUROPEAN HEART JOURNAL, 2015, 36 : 381 - 382
[2] The impact of time from diagnosis at baseline on long-term outcome in the GRIPHON Study: Selexipag in pulmonary arterial hypertension (PAH)
Gaine, S.
Sitbon, O.
Channick, R.
Chin, K.
Di Scala, L.
Galie, N.
Hoeper, M. M.
McLaughlin, V
Preiss, R.
Rubin, L.
Simonneau, G.
Tapson, V
Ghofrani, H. A.
Lang, I
PNEUMOLOGIE, 2020, 74 : S63 - S63
[3] Effect of Selexipag on Morbidity/Mortality in Pulmonary Arterial Hypertension: Results of the GRIPHON Study
Galie, N.
Channick, R.
Chin, K.
Frey, A.
Gaine, S.
Ghofrani, A.
Hoeper, M.
Lang, I.
McLaughlin, V.
Preiss, R.
Rubin, L. J.
Sitbon, O.
Stefani, M.
Tapson, V.
Simonneau, G.
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2015, 34 (04): : S163 - S163
[4] EFFECT OF SELEXIPAG ON MORBIDITY/MORTALITY IN PULMONARY ARTERIAL HYPERTENSION: RESULTS OF THE GRIPHON STUDY
McLaughlin, Vallerie V.
Channick, Richard
Chin, Kelly
Frey, Aline
Gaine, Sean
Ghofrani, Ardeschir
Hoeper, Marius
Lang, Irene
Preiss, Ralph
Rubin, Lewis J.
Simonneau, Gerald
Sitbon, Olivier
Stefani, Mylene
Tapson, Victor
Galie, Nazzareno
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (10) : A1538 - A1538
[5] Long-term survival and safety with selexipag in patients with pulmonary arterial hypertension: results from the GRIPHON study and its open-label extension
Galie, N.
Gaine, S.
Channick, R.
Ghofrani, H. A.
Hoeper, M.
Lang, I.
McLaughlin, V.
Preiss, R.
Rubin, L.
Shiraga, Y.
Simonneau, G.
Sitbon, O.
Tapson, V.
Chin, K.
EUROPEAN HEART JOURNAL, 2018, 39 : 631 - 632
[6] LONG-TERM SURVIVAL AND SAFETY WITH SELEXIPAG IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: RESULTS FROM THE GRIPHON STUDY AND ITS OPEN-LABEL EXTENSION
Coghlan, J. G.
Galie, N.
Gaine, S.
Channick, R.
Ghofrani, H-A
Hoeper, M.
Lang, I.
McLaughlin, V.
Preiss, R.
Rubin, L.
Shiraga, Y.
Simonneau, G.
Sitbon, O.
Tapson, V.
Chin, K.
THORAX, 2018, 73 : A76 - A77
[7] Association of NT-proBNP and Long-Term Outcome in Pulmonary Arterial Hypertension (PAH): Insights from the Phase III GRIPHON Study with Selexipag
Chin, K. M.
Rubin, L. J.
Channick, R.
Di Scala, L.
Gaine, S.
Galie, N.
Ghofrani, H. A.
Hoeper, M. M.
Lang, I. M.
Preiss, R.
Simonneau, G.
Sitbon, O.
McLaughlin, V. V.
Tapson, V. F.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
[8] The Impact of Time from Diagnosis at Baseline on Long-Term Outcome in the GRIPHON Study: Selexipag in Pulmonary Arterial Hypertension
Gaine, S. P.
Sitbon, O.
Channick, R. N.
Chin, K. M.
Di Scala, L.
Galie, N.
Hoeper, M. M.
McLaughlin, V.
Preiss, R.
Rubin, L. J.
Simonneau, G.
Tapson, V.
Ghofrani, H. A.
Lang, I. M.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
[9] Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension
Nazzareno Galiè
Sean Gaine
Richard Channick
J. Gerry Coghlan
Marius M. Hoeper
Irene M. Lang
Vallerie V. McLaughlin
Cheryl Lassen
Lewis J. Rubin
Shu-Fang Hsu Schmitz
Olivier Sitbon
Victor F. Tapson
Kelly M. Chin
Advances in Therapy, 2022, 39 : 796 - 810
[10] Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension
Galie, Nazzareno
Gaine, Sean
Channick, Richard
Coghlan, J. Gerry
Hoeper, Marius M.
Lang, Irene M.
McLaughlin, Vallerie V.
Lassen, Cheryl
Rubin, Lewis J.
Hsu Schmitz, Shu-Fang
Sitbon, Olivier
Tapson, Victor F.
Chin, Kelly M.
ADVANCES IN THERAPY, 2022, 39 (01) : 796 - 810

← 1 2 3 4 5 →